PFIZER INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Public

Established: 1849-01-01

Employees: 88K

Market Cap: $163.3B

Website: http://www.pfizer.com

Clinical Trials

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: 13-valent pneumococcal conjugate vaccine
Biological: 20-valent pneumococcal conjugate vaccine

First Posted Date: 2020-08-28

Last Posted Date: 2023-04-21

Lead Sponsor: Pfizer

Target Recruit Count: 668

Registration Number: NCT04530838

Locations: 🇯🇵
Inami Pediatrics, Setagaya-ku, Tokyo, Japan
🇯🇵
Saitoh-Clinic, Nishitokyo-shi, Tokyo, Japan
🇯🇵
Futaba Clinic, Shinjuku-ku, Tokyo, Japan

and more 35 locations

Safety and Immunogenicity of 20vPnC Coadministered With SIIV in Adults ≥65 Years of Age

Phase 3

Completed

Conditions: Pneumococcal Disease

Interventions: Biological: Experimental 20-valent pneumococcal conjugate vaccine (20vPnC)
Other: Saline
Biological: Influenza vaccine

First Posted Date: 2020-08-26

Last Posted Date: 2022-07-08

Lead Sponsor: Pfizer

Target Recruit Count: 1796

Registration Number: NCT04526574

Locations: 🇺🇸
Indago Research and Health Center, Inc., Hialeah, Florida, United States
🇺🇸
Coastal Carolina Research Center, North Charleston, South Carolina, United States
🇺🇸
East Valley Gastroenterology and Hepatology Associates, Chandler, Arizona, United States

and more 50 locations

Effectiveness of Treatment With Tofacitinib in Patients With Psoriatic Arthritis in Routine Clinical Practice

Completed

Conditions: Psoriatic Arthritis

First Posted Date: 2020-08-18

Last Posted Date: 2024-10-10

Lead Sponsor: Pfizer

Target Recruit Count: 116

Registration Number: NCT04517669

Locations: 🇮🇱
Hadassah University Hospital - Ein Kerem, Jerusalem, Israel
🇮🇱
Hadassah Hebrew University Medical Center - Ein Kerem, Jerusalem, Israel
🇮🇱
Meir Medical Center, Kfar- Sava, Israel

and more 47 locations

A Dose-Ranging Study With Vupanorsen (TRANSLATE-TIMI 70)

Phase 2

Completed

Conditions: Hyperlipidemias
Dyslipidemias
Hyperlipoproteinemias

Interventions: Drug: Vupanorsen
Drug: Placebo

First Posted Date: 2020-08-18

Last Posted Date: 2022-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 286

Registration Number: NCT04516291

Locations: 🇺🇸
Horizon Clinical Research Associates, PLLC, Gilbert, Arizona, United States
🇨🇦
GNMI MRI and CT Medical Imaging, Mississauga, Ontario, Canada
🇨🇦
Aggarwal and Associates Limited, Brampton, Ontario, Canada

and more 109 locations

PLACEBO-CONTROLLED SAFETY STUDY OF RITLECITINIB (PF-06651600) IN ADULTS WITH ALOPECIA AREATA

Phase 2

Terminated

Conditions: Alopecia Areata

Interventions: Drug: PF-06651600
Drug: Placebo

First Posted Date: 2020-08-18

Last Posted Date: 2024-06-18

Lead Sponsor: Pfizer

Target Recruit Count: 71

Registration Number: NCT04517864

Locations: 🇺🇸
Stony Brook Dermatology, Stony Brook, New York, United States
🇨🇦
Lynderm Research Inc., Markham, Ontario, Canada
🇺🇸
Marvel Clinical Research 002, LLC, Huntington Beach, California, United States

and more 36 locations

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Phase 4

Completed

Conditions: Metastatic Non Small Cell Lung Cancer

Interventions: Drug: Dacomitinib

First Posted Date: 2020-08-13

Last Posted Date: 2024-04-05

Lead Sponsor: Pfizer

Target Recruit Count: 101

Registration Number: NCT04511533

Locations: 🇮🇳
Artemis hospital, Gurugram, Haryana, India
🇮🇳
Apex Wellness Hospital, Nashik, Maharashtra, India
🇮🇳
Gujarat Hospital - Gastro & Vascular Centre, Surat, Gujarat, India

and more 12 locations

Study To Evaluate The Impact Of Early Initiation Of Biological Treatment With Ankylosing Spondylitis

Completed

Conditions: Ankylosing Spondylitis

Interventions: Drug: Etanercept

First Posted Date: 2020-08-11

Last Posted Date: 2021-10-28

Lead Sponsor: Pfizer

Target Recruit Count: 763

Registration Number: NCT04507763

Locations: 🇮🇶
Pfizer, Baghdad, Iraq

Study To Evaluate The Efficacy And Long-Term Adherence Of Spondyloarthropathies(SpA) Patients On Enbrel

Completed

Conditions: Spondyloarthrosis

Interventions: Drug: Etanercept

First Posted Date: 2020-08-11

Last Posted Date: 2021-10-04

Lead Sponsor: Pfizer

Target Recruit Count: 763

Registration Number: NCT04507776

Locations: 🇮🇶
Pfizer, Baghdad, Iraq

A Study of the Long-Term Safety of Crisaborole Ointment, 2% in Japanese Pediatric and Adult Participants With Mild to Moderate Atopic Dermatitis

Phase 3

Terminated

Conditions: Atopic Dermatitis

Interventions: Drug: Crisaborole 2%

First Posted Date: 2020-08-04

Last Posted Date: 2021-08-12

Lead Sponsor: Pfizer

Target Recruit Count: 40

Registration Number: NCT04498403

Locations: 🇯🇵
Mildix Skin Clinic, Adachi-ku, Tokyo, Japan
🇯🇵
Sugamo Kobayashi Derma Clinic, Toshima-Ku, Tokyo, Japan
🇯🇵
Takagi Dermatological Clinic, Obihiro, Hokkaido, Japan

and more 8 locations

TREATMENT AND MONITORING PATTERNS AND CLINICAL OUTCOMES IN PATIENTS RECEIVING PALBOCICLIB COMBINATION TREATMENT (WITH AI OR FULVESTRANT) FOR HR+/HER2- A/MBC IN A COMMUNITY ONCOLOGY SETTING.

Completed

Conditions: Breast Cancer

First Posted Date: 2020-08-04

Last Posted Date: 2020-08-04

Lead Sponsor: Pfizer

Target Recruit Count: 1

Registration Number: NCT04498481

Locations: 🇺🇸
Pfizer United States, New York, New York, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy